Pharma, Pharmaceutics and Biotechnology Conference

A big challenge in the management of cardiovascular diseases remains effective drug delivery, which is still one of the major causes of morbidity and mortality across all sectors of society.

The session will discuss some new innovative drug delivery systems specially designed for cardiovascular therapies and how such systems improve therapeutic efficacy and patient’s outcomes. These include long-term treatment for cardiovascular diseases, which involve heart failure, hypertension, and coronary artery disease. The conventional drug delivery systems could at times provide inadequate therapeutic concentration; there is low patient compliance, and toxic side effects are augmented.

It thus necessitates scientists to target the development of advanced drug delivery systems, offering controlled release and better bioavailability to the targeted therapy. Nanoparticles and liposomes are fast becoming two of the most promising delivery systems in cardiovascular drug therapy. Such carriers encapsulate therapeutic agents and protect them from degradation while enhancing their bioavailability.

Upon modification of the surface properties of such delivery systems, drugs may be released at targeted sites within the cardiovascular system, with a lowering of systemic exposure and subsequent decrease in side effects. Formulations designed with a controlled and time-dependent drug release are another important drug delivery aspect of cardiovascular diseases.

These maintain therapeutic drug levels for a long period by sustaining drug levels over time, thus increasing patient compliance and lowering the dosing frequency. It is quite useful for chronic cardiovascular diseases where continuous levels of a drug guarantee optimum management.

The next relevant aspect in the development of drug delivery systems, especially for cardiovascular drugs deals with their pharmacokinetics. The absorption, distribution, metabolism, and excretion of drugs are important resources for a scientist while designing better therapies.

Pharmacokinetic studies form an essential aspect of this session as part of streamlining strategies for delivery of drugs in cardiovascular applications. Patient adherence is a critical determinant of the success of cardiovascular therapy. Innovative drug delivery system can significantly enhance patient adherence by making drug dosing regimens simpler or providing sustained release. Better management of cardiovascular diseases can be achieved by alerting patients about their therapies and the advantages of advanced drug delivery systems.

This session will present the latest advancements in drug delivery related to cardiovascular diseases, bringing together up-to-date information on innovation in delivery systems, targeting mechanisms, and strategies toward improving patient adherence, needed by those seeking to develop cardiovascular pharmacotherapy.